Predict your next investment

Corporation
HEALTHCARE | Pharmaceutical Distribution & Wholesale
yuhan.co.kr

See what CB Insights has to offer

Investments

16

Portfolio Exits

2

Partners & Customers

10

About Yuhan

Yuhan (KRX: 000100) is a global pharmaceutical company that focuses on primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients.

Yuhan Headquarter Location

74, Noryangjin-ro Dongjak-gu

Seoul, 06927,

South Korea

+82-2-828-0181

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Yuhan

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Yuhan in 1 Expert Collection, including Beauty & Personal Care.

B

Beauty & Personal Care

858 items

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

Yuhan Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Yuhan Rank

Latest Yuhan News

Yuhan Corp.: 1Q22 Review: Plenty More Than Lazertinib

May 2, 2022

Yuhan Corp.: 1Q22 Review: Plenty More Than Lazertinib Share Yuhan Corp.: 1Q22 Review: Plenty More Than Lazertinib By Kim Tae-hee   Maintain BUY, target price of KRW75,000        We maintain BUY and TP of KRW75,000 on Yuhan Corp. The company’s appeal lies in: (1) the self-developed drug Leclaza (lazertinib), which has established a presence in the domestic market and is expected to fare well overseas; (2) a candidate substance currently licensed out to pharmas (incl. Gilread, Boehringer Ingelheim, Spine BioPharma); and (3) potential technology transfers of drugs in the pipeline. However, earnings momentum may slow on increased ad spending on new business. 1Q22 revenue in line with estimates; sluggish OP due to ad spending      Yuhan posted 1Q22 consolidated revenue/OP of KRW410.9bn (+8.4% YoY)/KRW6.1bn (-56.1% YoY); revenue was in line but OP fell well below. There was growth across the board: +8.7% YoY for Pharmaceuticals, +19.1% YoY for Household & Healthcare, +65.0% YoY for Overseas and +61.5% YoY for special-purpose segments. OPM dropped to 1.5% on plunging license fees (KRW14.0bn in 1Q21→KRW1.5bn in 1Q22) and surging ad spending for Y’s Biome and the pet business. Plenty of candidate substances aside from lazertinib  Lazertinib, which accounts for the largest portion of Yuhan EV, has standalone Phase 3 trial/concomitant test results (with amivantamab) pending. Attention should now be turned to candidate substances other than lazertinib. YH12852 (Processa Pharmaceuticals-licensed gastrointestinal disorder drug) began Phase 2a tests, and YH14618 (Spine BioPharma degenerative disc drug) passed Phase 2 (Phase 3 approved). Others include YH32367 (HER2 x 4-1BB; ABL Bio-licensed bispecific antibody; Phase 1 trials beginning) and YH25724 (Boehringer Ingelheim NASH drug; Phase 1a trials ended). POPULAR

Yuhan Investments

16 Investments

Yuhan has made 16 investments. Their latest investment was in MediRama as part of their Corporate Minority on April 4, 2022.

CBI Logo

Yuhan Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/4/2022

Corporate Minority

MediRama

Yes

1

1/17/2022

Private Equity - II

ImmuneOncia

$20.5M

No

1

12/28/2021

Series C

HUINNO

$36.62M

No

2

6/21/2021

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

6/15/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/4/2022

1/17/2022

12/28/2021

6/21/2021

6/15/2021

Round

Corporate Minority

Private Equity - II

Series C

Corporate Minority

Series C

Company

MediRama

ImmuneOncia

HUINNO

Subscribe to see more

Subscribe to see more

Amount

$20.5M

$36.62M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Yuhan Portfolio Exits

2 Portfolio Exits

Yuhan has 2 portfolio exits. Their latest portfolio exit was Syntekabio on December 17, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/17/2019

IPO

2

9/21/2018

IPO

Subscribe to see more

Subscribe to see more

10

Date

12/17/2019

9/21/2018

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

2

10

Yuhan Partners & Customers

10 Partners and customers

Yuhan has 10 strategic partners and customers. Yuhan recently partnered with Spine BioPharma on April 4, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

4/11/2022

Licensee

United States

Yuhan’s US partner to start P3 study for degenerative disc treatment

Spine Biopharma , Yuhan Corp. 's U.S. partner , has received FDA approval to conduct a phase 3 study for a degenerative disc treatment candidate , YH14618 .

1

10/13/2021

Partner

United States

Yuhan’s GI disorder drug enters phase 2 trial in US

Yuhan Corp. said its U.S. partner Processa Pharmaceuticals obtained the FDA nod to conduct a phase 2a trial of PCS12852 , a drug candidate for GI motility disorders .

1

4/8/2021

Licensor

South Korea

[Herald Interview] Despite high hurdles, Korea bent on developing drugs

Mook said the partnership among Yuhan , Oscotec and Yonsei University is a preferable partnership model that the Korea Drug Development Fund aims to forge more of in the future .

1

3/15/2021

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

8/20/2020

Licensee

United States

Subscribe to see more

Subscribe to see more

10

Date

4/11/2022

10/13/2021

4/8/2021

3/15/2021

8/20/2020

Type

Licensee

Partner

Licensor

Partner

Licensee

Business Partner

Country

United States

United States

South Korea

South Korea

United States

News Snippet

Yuhan’s US partner to start P3 study for degenerative disc treatment

Spine Biopharma , Yuhan Corp. 's U.S. partner , has received FDA approval to conduct a phase 3 study for a degenerative disc treatment candidate , YH14618 .

Yuhan’s GI disorder drug enters phase 2 trial in US

Yuhan Corp. said its U.S. partner Processa Pharmaceuticals obtained the FDA nod to conduct a phase 2a trial of PCS12852 , a drug candidate for GI motility disorders .

[Herald Interview] Despite high hurdles, Korea bent on developing drugs

Mook said the partnership among Yuhan , Oscotec and Yonsei University is a preferable partnership model that the Korea Drug Development Fund aims to forge more of in the future .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Yuhan Team

1 Team Member

Yuhan has 1 team member, including former Managing Director, BOB SHIN.

Name

Work History

Title

Status

BOB SHIN

Palo Alto Investors, Burrill & Company, CJ CheilJedang, DAOL Investment, and Hana Bank

Managing Director

Former

Name

BOB SHIN

Work History

Palo Alto Investors, Burrill & Company, CJ CheilJedang, DAOL Investment, and Hana Bank

Title

Managing Director

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.